Literature DB >> 32888124

High-throughput microRNA profile in adult and pediatric primary glioblastomas: the role of miR-10b-5p and miR-630 in the tumor aggressiveness.

Luiz Guilherme Darrigo Junior1, Mirella Baroni2, Régia Caroline Peixoto Lira1,3, Silvia Teixeira1, Paola Fernanda Fedatto1, Vanessa Silva Silveira2, Veridiana Kill Suazo1, Luciana Chain Veronez1, Rodrigo Alexandre Panepucci4, David Santos Marco Antônio5, José Andres Yunes6,7, Silvia Regina Brandalise6, Simone Dos Santos Aguiar7, Luciano Neder8, Ricardo Santos de Oliveira9, Hélio Rubens Machado9, Carlos Gilberto Carlotti9, Luiz Gonzaga Tone1,2, Elvis Terci Valera1, Carlos Alberto Scrideli10.   

Abstract

Glioblastoma (GBM) is the most common primary malignant neoplasm of the central nervous system and, despite the standard therapy; the patients' prognoses remain dismal. The miRNA expression profiles have been associated with patient prognosis, suggesting that they may be helpful for tumor diagnosis and classification as well as predictive of tumor response to treatment. We described the microRNA expression profile of 29 primary GBM samples (9 pediatric GBMs) and 11 non-neoplastic white matter samples as controls (WM) by microarray analysis and we performed functional in vitro assays on these 2 most differentially expressed miRNAs. Hierarchical clustering analysis showed 3 distinct miRNA profiles, two of them in the GBM samples and a group consisting only of cerebral white matter. When adult and pediatric GBMs were compared to WM, 37 human miRNAs were found to be differentially expressed, with miR-10b-5p being the most overexpressed and miR-630 the most underexpressed. The overexpression of miR-630 was associated with reduced cell proliferation and invasion in the U87 GBM cell line, whereas the inhibition of miR-10b-5p reduced cell proliferation and colony formation in the U251 GBM cell line, suggesting that these miRNAs may act as tumor-suppressive and oncogenic miRNAs, respectively. The present study highlights the distinct epigenetic profiling of adult and pediatric GBMs and underscores the biological importance of mir-10b-5p and miR-630 for the pathobiology of these lethal tumors.

Entities:  

Keywords:  Glioblastoma; miR-10b; miR-630; miRNA

Mesh:

Substances:

Year:  2020        PMID: 32888124     DOI: 10.1007/s11033-020-05754-3

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  48 in total

1.  Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease.

Authors:  Barbara S Paugh; Chunxu Qu; Chris Jones; Zhaoli Liu; Martyna Adamowicz-Brice; Junyuan Zhang; Dorine A Bax; Beth Coyle; Jennifer Barrow; Darren Hargrave; James Lowe; Amar Gajjar; Wei Zhao; Alberto Broniscer; David W Ellison; Richard G Grundy; Suzanne J Baker
Journal:  J Clin Oncol       Date:  2010-05-17       Impact factor: 44.544

2.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.

Authors:  Quinn T Ostrom; Haley Gittleman; Peter Liao; Chaturia Rouse; Yanwen Chen; Jacqueline Dowling; Yingli Wolinsky; Carol Kruchko; Jill Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2014-10       Impact factor: 12.300

Review 3.  MicroRNA as potential biomarkers in Glioblastoma.

Authors:  Zammam Areeb; Stanley S Stylli; Rachel Koldej; David S Ritchie; Tali Siegal; Andrew P Morokoff; Andrew H Kaye; Rodney B Luwor
Journal:  J Neurooncol       Date:  2015-09-21       Impact factor: 4.130

Review 4.  MicroRNA-Based Drugs for Brain Tumors.

Authors:  Shubaash Anthiya; Audrey Griveau; Claire Loussouarn; Patrick Baril; Martin Garnett; Jean-Paul Issartel; Emmanuel Garcion
Journal:  Trends Cancer       Date:  2018-02-09

Review 5.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

6.  Extent of resection in patients with glioblastoma: limiting factors, perception of resectability, and effect on survival.

Authors:  Daniel Orringer; Darryl Lau; Sameer Khatri; Grettel J Zamora-Berridi; Kathy Zhang; Chris Wu; Neeraj Chaudhary; Oren Sagher
Journal:  J Neurosurg       Date:  2012-09-14       Impact factor: 5.115

7.  Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma.

Authors:  Graziella Filippini; Chiara Falcone; Amerigo Boiardi; Giovanni Broggi; Maria G Bruzzone; Dario Caldiroli; Rita Farina; Mariangela Farinotti; Laura Fariselli; Gaetano Finocchiaro; Sergio Giombini; Bianca Pollo; Mario Savoiardo; Carlo L Solero; Maria G Valsecchi
Journal:  Neuro Oncol       Date:  2007-11-09       Impact factor: 12.300

Review 8.  Long-term survival with glioblastoma multiforme.

Authors:  Dietmar Krex; Barbara Klink; Christian Hartmann; Andreas von Deimling; Torsten Pietsch; Matthias Simon; Michael Sabel; Joachim P Steinbach; Oliver Heese; Guido Reifenberger; Michael Weller; Gabriele Schackert
Journal:  Brain       Date:  2007-09-04       Impact factor: 13.501

9.  Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.

Authors:  Roger Stupp; Sophie Taillibert; Andrew Kanner; William Read; David Steinberg; Benoit Lhermitte; Steven Toms; Ahmed Idbaih; Manmeet S. Ahluwalia; Karen Fink; Francesco Di Meco; Frank Lieberman; Jay-Jiguang Zhu; Giuseppe Stragliotto; David Tran; Steven Brem; Andreas Hottinger; Eilon D. Kirson; Gitit Lavy-Shahaf; Uri Weinberg; Chae-Yong Kim; Sun-Ha Paek; Garth Nicholas; Jordi Bruna; Hal Hirte; Michael Weller; Yoram Palti; Monika E. Hegi; Zvi Ram
Journal:  JAMA       Date:  2017-12-19       Impact factor: 56.272

Review 10.  Therapeutic options in recurrent glioblastoma--An update.

Authors:  Katharina Seystahl; Wolfgang Wick; Michael Weller
Journal:  Crit Rev Oncol Hematol       Date:  2016-01-21       Impact factor: 6.312

View more
  1 in total

1.  Synergistic Effects of A Combined Treatment of Glioblastoma U251 Cells with An Anti-miR-10b-5p Molecule and An AntiCancer Agent Based on 1-(3',4',5'-Trimethoxyphenyl)-2-Aryl-1H-Imidazole Scaffold.

Authors:  Matteo Zurlo; Romeo Romagnoli; Paola Oliva; Jessica Gasparello; Alessia Finotti; Roberto Gambari
Journal:  Int J Mol Sci       Date:  2022-05-26       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.